Laurent Miglianico

Saint-malo, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Saint-malo, FR 

Overview

Laurent Miglianico practices practicing medicine in Saint-malo, France.

His clinical expertise encompasses Colorectal Cancer, Pancreatic Cancer, Paronychia, and Folliculitis.

He is actively involved in clinical research, co-authoring 11 peer reviewed articles and participating in 6 clinical trials.

Gender

Male

Locations

Saint-malo, 35403, France
Other Locations
Saint Grégoire, France
Centre Hospitalier Privé St Grégoire
Rennes, France
Centre Hospitalier Privé St Grégoire, Sete, France
Gustave Roussy
Villejuif, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
Enrollment Status: Recruiting
Publish Date: July 09, 2025
Intervention Type: Drug
Study Drugs: Oxaliplatin intravenous, 5 Fu, Folinic Acid, Oxaliplatin intra-arterial, Panitumumab, Bevacizumab
Study Phase: Phase 3
INtegratioN of Trastuzumab, With or Without Pertuzumab, Into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL
INtegratioN of Trastuzumab, With or Without Pertuzumab, Into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL
Enrollment Status: Completed
Publish Date: July 31, 2025
Intervention Type: Drug, Procedure
Study Drugs: Cisplatin, 5-fluorouracil or Capecitabine, Trastuzumab, Pertuzumab
Study Phase: Phase 2
Phase II Study Evaluating the Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years Old With a Metastatic Colorectal Adenocarcinoma .
Phase II Study Evaluating the Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years Old With a Metastatic Colorectal Adenocarcinoma .
Enrollment Status: Completed
Publish Date: February 23, 2024
Intervention Type: Drug
Study Phase: Phase 2
Randomized Phase II Study of First-line FOLFIRI Plus Cetuximab for 8 Cycles Followed by Either Single-agent Cetuximab as Maintenance Therapy or Observation in Patients With Wild-type KRAS and NRAS Metastatic Colorectal Cancer
Randomized Phase II Study of First-line FOLFIRI Plus Cetuximab for 8 Cycles Followed by Either Single-agent Cetuximab as Maintenance Therapy or Observation in Patients With Wild-type KRAS and NRAS Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: March 24, 2022
Intervention Type: Drug
Study Drugs: Cetuximab, FOLFIRI
Study Phase: Phase 2
Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers (IRAM)
Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers (IRAM)
Enrollment Status: Withdrawn
Publish Date: January 30, 2020
Intervention Type: Other, Radiation
Study Phase: Phase 2
Evaluation of an Immunomodulatory Maintenance Treatment in Patients With Metastatic Colorectal Cancer With Tumor Reduction During Induction Treatment
Evaluation of an Immunomodulatory Maintenance Treatment in Patients With Metastatic Colorectal Cancer With Tumor Reduction During Induction Treatment
Enrollment Status: Unknown
Publish Date: September 10, 2019
Intervention Type: Drug, Other
Study Drug: MGN1703
Study Phase: Phase 3
View 5 Less Clinical Trials

11 Total Publications

Relative dose intensity of first-line triplet chemotherapy in metastatic colorectal cancer.
Relative dose intensity of first-line triplet chemotherapy in metastatic colorectal cancer.
Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Published: November 03, 2023

Frequently Asked Questions about Laurent Miglianico

Is Laurent Miglianico a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Laurent Miglianico is classified as an Experienced expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Laurent Miglianico participate in research or clinical trials?

Yes. Laurent Miglianico has published 11 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Laurent Miglianico's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Miglianico's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile